Sun Pharma’s Q2 Results Exceed Expectations, Shares Show Resilience

Sun Pharma's Q2 Results Exceed Expectations, Shares Show Resilience

VoM News Desk | November 2, 2023 | 01:58 PM IST | Breaking News | Follow on Google News

Sun Pharma’s Q2 Results Exceed Expectations, Shares Show Resilience

Sun Pharma’s Q2 Results Exceed Expectations, Shares Show Resilience

Sun Pharma’s share price demonstrated strength in Thursday’s trading session following the company’s impressive Q2 results, which surpassed market expectations in both profit and revenue. The share price opened at an intraday high of ₹1,130.80 on the BSE, signifying renewed investor confidence.

Technical Analysis and Positive Market Sentiment

According to technical analysts, pharmaceutical stocks are currently in the spotlight, with Sun Pharma’s share price displaying remarkable strength during the session. Prices have rebounded convincingly after a recent sell-off, and a hammer formation is visible on the weekly chart. Analysts suggest that ₹1,100 serves as immediate support, while ₹1,180 could be a reasonable near-term target. As of 12:00 IST, Sun Pharma’s share price was trading at ₹1,126.75 per share, marking a 0.95% increase.

Robust Financial Performance in Q2

Sun Pharma reported a 5% year-on-year (YoY) rise in its consolidated net profit, reaching ₹2,375.5 crore for the July-September quarter, compared to ₹2,262.22 crore in the corresponding period of the previous year. Furthermore, the company’s revenue witnessed substantial growth, with an increase of over 11% YoY to ₹12,192 crore in the quarter, compared to ₹10,952.3 crore in the same quarter last year.

Analyst Recommendations and Target Price Revisions

Brokerages have been optimistic about Sun Pharma’s Q2 results, with some stating that the company either met or nearly exceeded their estimates. As a result, brokerages have maintained their “buy” rating for the stock and have adjusted their target prices for Sun Pharma shares.

• Motilal Oswal Financial Services: The brokerage indicated that Sun Pharma’s Q2FY24 financial performance was in line with expectations. The company’s specialized and branded generics divisions experienced strong growth, and it continues to pursue its objectives, including increasing prescriptions for specialized products, introducing new products, and conducting clinical studies. The brokerage maintained its target price at ₹1,310.
• Nuvama Institutional Equities: The brokerage considered Sun Pharma’s Q2FY24 results to be in line with consensus. Notable aspects included India’s recovery, the progress in the specialty segment, and the potential approval of deuruxolitinib by FY26. The brokerage reaffirmed its “BUY” rating with a target price of ₹1,330.
• Kotak Institutional Equities: According to Kotak, Sun Pharma’s Q2 results represented a well-rounded performance. Despite challenges such as the Mohali consent decree and lower gRevlimid sales, the company’s performance exceeded or matched expectations. Kotak retained an “ADD” rating on Sun Pharma with a revised fair value of ₹1,280, emphasizing its position as a top pick in the pharmaceutical sector.

Sun Pharma’s strong Q2 results and positive outlook have led to increased investor interest and optimistic ratings from financial analysts.

Disclaimer: The opinions and suggestions provided in this article are those of individual analysts and do not reflect the viewpoints of VoM News. We encourage investors to consult with certified experts before making any investment choices.

Sun Pharma’s Q2 Results Exceed Expectations, Shares Show Resilience:In case of rectification of any error in this Article, Visit on Correction Policy or Register your Query

VoM News Desk

VoM News is an online web portal in jammu Kashmir offers regional, National & global news.